JAK3 Recombinant Monoclonal Antibody

說明書

中文名稱：

JAK3重組抗體
貨號：

CSB-RA206737A0HU
規格：

￥1320
圖片：
IHC image of CSB-RA206737A0HU diluted at 1:100 and staining in paraffin-embedded human lung cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品描述：

CSB-RA206737A0HU JAK3重組單克隆抗體是針對Janus激酶3（JAK3）研發的高特異性檢測工具，適用于多種實驗場景。JAK3作為酪氨酸激酶家族成員，在細胞因子介導的免疫信號轉導中發揮核心作用，其表達與淋巴細胞活化、增殖及免疫調控密切相關。該抗體經嚴格驗證，在ELISA和免疫組化（IHC）實驗中展現出優異性能，IHC推薦使用1:50-1:200稀釋度，可清晰檢測福爾馬林固定石蠟包埋組織中JAK3蛋白的定位與表達水平。實驗數據顯示，該抗體具有高親和力和低交叉反應性，能夠在多種生物樣本中實現穩定檢測，為研究JAK/STAT信號通路在免疫疾病、血液系統異常或炎癥模型中的功能提供可靠支持。其重組單克隆特性確保了批次間高度一致性，適用于體外蛋白定量分析、組織分布研究及分子機制探索等科研領域，為靶向JAK3的基礎研究提供精準實驗工具。
Uniprot No.：

P52333
基因名：

JAK3
別名：

Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK), JAK3
反應種屬：

Human
免疫原：

A synthesized peptide derived from human JAK3
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

1C7
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion.
基因功能參考文獻：
1. JAK3 mutations in Italian patients affected by SCID: New molecular aspects of a long-known gene. PMID: 30032486
2. we report the results of a screening for mutations in SETBP1 and JAK3 of a cohort of seventy Italian patients with juvenile myelomonocytic leukemia, identifying 11.4% of them harboring secondary mutations in these two genes and discovering two new mutations in the SKI domain of SETBP1 PMID: 26980750
3. Jak3-mediated phosphorylation of beta-catenin suppressed EGF-mediated epithelial-mesenchymal transition and facilitated epithelial barrier functions by AJ localization of phosphorylated beta-catenin through its interactions with alpha-catenin. PMID: 28821617
4. frequency of JAK3 mutations in the JH2 domain was relatively low in extranodal natural killer/T-cell lymphoma, nasal type (NTCL) in contrast to a previous report; study identified novel JAK3H583Y- and JAK3G589D-activating mutations that were oncogenic and sensitive to a JAK3 inhibitor PMID: 28284718
5. In natural killer/T-cell lymphoma (NKTL) as a disease model, phosphorylation of EZH2 by JAK3 promotes the dissociation of the PRC2 complex leading to decreased global histone H3 lysine 27 methylation levels. PMID: 27297789
6. JAK3 mediates smooth muscle cell proliferation and survival during injury-induced vascular remodeling. PMID: 28473442
7. Data indicate that phosphorylation of Janus kinase 3 (JAK3) and STAT3 transcription factor (STAT3) was inhibited by latent membrane protein 1 (LMP1)-IgG. PMID: 28009988
8. analysis of JAK3 kinetic mechanism and inhibition by tofacitinib PMID: 27555492
9. patient had a homozygote of the JAK3 mutation, and her parents were heterozygous carriers. PMID: 27593409
10. JAK3 up-regulates SGLT1 activity by increasing the carrier protein abundance in the cell membrane, an effect enforcing cellular glucose uptake into activated lymphocytes and thus contributing to the immune response. PMID: 27595398
11. JAK3 and MCL-1 were down-regulated in patient CD8(+) T cells versus their normal counterparts, likely due to defective suppressor activity of miR-29b and miR-198 in RCC CD8(+) T cells. PMID: 27063186
12. N225K and A550V PTPN6 mutations cause loss-of-function leading to JAK3 mediated deregulation of STAT3 pathway and uncover a mechanism that tumor cells can use to control PTPN6 substrate specificity. PMID: 26565811
13. Study shows JAK3 mutations in 16% of patients with T-cell prolymphocytic leukemia which might be an important prognostic marker. PMID: 26493028
14. This study showed that JAK3 is a powerful negative regulator of the creatine transporter SLC6A8. PMID: 26666525
15. Letter/Case Report: ersistent rotavirus diarrhea post-transplant in a novel JAK3-SCID patient after vaccination. PMID: 26248889
16. interleukin-4 regulates hematopoietic lineage choice by activating the JAK3-STAT6 pathway, which causes dendritic-cell-specific DNA demethylation. PMID: 26829670
17. Foxp3 has a rapid turn over in Treg partly controlled at the transcriptional level by the JAK/STAT pathway PMID: 27077371
18. Results confirm that JAK3 is mutated in T-PLL and underscore the potential therapeutical relevance of epigenetic regulator. PMID: 26917488
19. Data provide the first evidence that de-regulated Jak3/STAT3/STAT5 signalling in CTCL cells represses the expression of the gene encoding miR-22, a novel tumor suppressor miRNA. PMID: 26244872
20. Study describes three patients with a novel deep intronic mis-splicing mutation in JAK3 as a cause of T-B+NK- severe combined immunodeficiency. PMID: 26769277
21. Jak3 has a role in promoting mucosal tolerance through suppressed expression and limiting activation of TLRs thereby preventing intestinal and systemic chronic low-grade inflammation and associated obesity and MetS PMID: 26451047
22. that JAK3 may contribute to the pathogenesis of pediatric ALL and serve as an important therapeutic target which can be leveraged to improve outcomes for pediatric patients with ALL. PMID: 25146434
23. These results do not confirm association between JAK3 polymorphisms and cardiovascular disease in rheumatoid arthritis. PMID: 25815310
24. Activating Janus kinase 3 mutation is associated with mycosis fungoides. PMID: 26082451
25. The study reports the first patient with relapsed pediatric Early T-cell precursor acute lymphoblastic leukemia to exhibit a homozygous JAK3 activating mutation, V674A, caused by acquired uniparental disomy. PMID: 25430085
26. JAK inhibitor ruxolitinib (that inhibits mainly the JAK3/STAT5 pathway) affects key characteristics of human NK cells, such as cytokine-induced expansion and killing via an impaired cytokine-mediated NK cell activation PMID: 25832652
27. Case Report: JAK3 mutations giving rise to common variable immunodeficiency mimicking late-onset combined immunodeficiency. PMID: 26182690
28. These results suggest irreversible inhibitors of this class may be useful selective agents, both as tools to probe Jak3 biology and potentially as therapies for autoimmune diseases. PMID: 25552479
29. no JAK3 mutations (A572V or A573V) were identified in samples of NK cell neoplasms and EBV-associated T/NK cell lymphoproliferative diseasein Japan PMID: 23808814
30. in extranodal natural killer/T cell lymphomas, phosphorylated JAK3 expression does not necessarily harbor exon 13 mutations. PMID: 24965108
31. JAK3/STAT5 signaling via IL-2 receptor is necessary to maintain the long-term expression of the high-affinity alpha beta gamma(c)-receptor of IL-2 and optimal proliferation of blood lymphocytes. PMID: 25509109
32. Report activated JAK3 variant in myelodysplastic syndromes. PMID: 24674452
33. we not only characterize Jak3 interaction with Shc, but also demonstrate the molecular mechanism of intracellular regulation of Jak3 activation PMID: 24795043
34. The finding of recurrent activating JAK3 mutations in patients with T-PLL could enable the use of JAK3 inhibitors to treat patients with this unfavorable malignancy who otherwise have a very poor prognosis. PMID: 24446122
35. JAK3 is a powerful regulator of the peptide transporters PEPT1 and PEPT2. PMID: 23934551
36. In cervical cancer cells the phosphorylation of STAT5/JAK3 increases at low doses of IL-2 but significantly decreases at high doses. PMID: 24548303
37. JAK3 mutations are found in a subset of clear cell renal cell carcinoma patients and may be associated with its development and a greater risk of metastases PMID: 21868263
38. the essential role of Jak3 in the colon where it facilitated mucosal differentiation by promoting the expression of differentiation markers and enhanced colonic barrier functions through AJ localization of beta-catenin. PMID: 24045942
39. Mutations of SETBP1 and JAK3 were common recurrent secondary events presumed to be involved in tumor progression and were associated with poor clinical outcomes. PMID: 23832011
40. Hypomorphic Janus kinase 3 mutations result in a spectrum of immune defects, including partial maternal T-cell engraftment. PMID: 23384681
41. analysis of the JAK-Fes-phospholipase D signaling pathway that is enhanced in highly proliferative breast cancer cells PMID: 23404507
42. Data suggest that cross-talk occurs between cAMP/PKA and the IL-2R beta/Jak3/Stat5b cascade in T-cells. PMID: 23341462
43. Data indicate that the invasive phenotype of MDA-MB-231 cells is mediated by phospholipase D2 (PLD2) under direct regulation of both Janus kinase 3 (JAK3) and tepidermal growth factor receptor (EGFR). PMID: 23238254
44. analysis of molecular mechanism of interactions between Jak3 and cytoskeletal proteins where tyrosine phosphorylation of the SH2 domain acted as an intramolecular switch for the interactions between Jak3 and cytoskeletal proteins PMID: 23012362
45. Data suggest that Janus kinase 3 (JAK3) may play a significant role in the pathogenesis of natural killer/T-cell lymphoma (NKTCL). PMID: 22705984
46. JAK3 mutations are associated with response to therapy in T-cell acute lymphoblastic leukemia. PMID: 22425895
47. peripheral blood lymphocytes (PBLs) of ovarian cancer patients showed lower JAK3, CD3-zeta molecules expression levels, as well as lower STAT3 and CD3-zeta phosphorylation levels than cells of control. PMID: 22221142
48. analysis of the biochemistry, immunological functions, and clinical significance of JAK3 [review] PMID: 22130498
49. Data imply that IL-21-mediated signaling is critical for long-lived humoral immunity and to restore antibody responses in IL2RG/JAK3-deficient patients after hematopoietic cell transplantation. PMID: 22039266
50. Review: discuss role of JAK3 inhibitors as immunosuppressive agents in kidney transplantation. PMID: 21971513
顯示更多

收起更多
相關疾病：

Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID)
亞細胞定位：

Endomembrane system; Peripheral membrane protein. Cytoplasm.
蛋白家族：

Protein kinase superfamily, Tyr protein kinase family, JAK subfamily
組織特異性：

In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins.
數據庫鏈接：

HGNC: 6193

OMIM: 600173

KEGG: hsa:3718

STRING: 9606.ENSP00000391676

UniGene: Hs.515247

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human